The accounting fix removes a key Nasdaq delisting risk and paves the way for the Series A conversion and change of control. Monitor the Annual Meeting vote outcome on September 17 — approval is critical for continued listing and the Azora merger integration.
Price Chart
Executive Summary
Adial Pharmaceuticals filed definitive additional proxy materials (DEFA14A) on September 16, 2026, amending the Securities Purchase Agreement and Note Exchange Agreements to remove the Penalty Provision, which reclassifies $22.7 million of Milestone Warrant rights from liability to equity. This accounting fix is intended to restore Nasdaq compliance ahead of the September 17, 2026 Annual Meeting, where stockholders will vote on the conversion of Series A Preferred Stock into common stock, triggering a change of control.
Key Financial Metrics
Key Facts
- Amendments remove the Penalty Provision, reclassifying $22.7 million of Milestone Warrant rights from liability to equity.
- Pro forma balance sheet shows stockholders' equity improving from a deficit of ($38.4 million) to positive $22.9 million.
- Annual Meeting scheduled for September 17, 2026, to vote on conversion of 12,930.617 Series A Preferred shares into 12,930,617 common shares.
- Conversion will result in a change of control under Nasdaq Listing Rules 5635(a) and 5635(b).
- Company had fallen below Nasdaq's minimum stockholders' equity requirement as of June 30, 2026.
Financial Impact
Reclassification of $22.7 million from liability to equity; pro forma stockholders' equity moves from ($38.4 million) to $22.9 million.
Risk Factors
- Stockholder vote on Series A conversion may not pass, jeopardizing Nasdaq listing.
- Remaining $1.1 million of Milestone Warrant rights liability still classified as liability if additional Note Exchange amendments are not executed.
- Change of control could trigger further dilution or governance shifts.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-100607 |
| Document: 0001213900-26-100607-index-headers.html | 0001213900-26-100607 |
| Document: 0001213900-26-100607-index.html | 0001213900-26-100607 |
| Document: 0001213900-26-100607.txt | 0001213900-26-100607 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | EFFECT | $3.68 | awaiting T+60 | — | $3.81 (−3.40%) |
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.81 (+7.42%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.81 (+7.42%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.81 (−5.11%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.81 (−5.11%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.81 (−7.87%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.81 (−13.52%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.81 (−13.52%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.81 (−26.97%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.81 (−26.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers